Skip to main content

AnaptysBio, Inc. (ANAB)

NASDAQ: ANAB · IEX Real-Time Price · USD
31.12 -0.68 (-2.14%)
Nov 26, 2021 1:00 PM EST - Market closed

Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation.

The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

AnaptysBio, Inc.
AnaptysBio Logo
CountryUnited States
Founded2005
IPO DateJan 26, 2017
IndustryBiotechnology
SectorHealth Care
Employees94
CEOHamza Suria

Contact Details

Address:
10421 Pacific Center Ct Ste 200
San Diego, California 92121-4339
United States
Phone858 362 6295
Websiteanaptysbio.com

Stock Details

Ticker SymbolANAB
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001370053

Key Executives

NamePosition
Hamza SuriaPresident, Chief Executive Officer and Director
Dennis M. MulroyChief Financial Officer
Dr. Paul F. LizzulChief Medical Officer
Eric J. LoumeauChief Operating Officer and General Counsel
Beth MuellerSenior Vice President of Human Resources
Dr. Margaret MarinoSenior Vice President of Project Management

Latest SEC Filings

DateTypeTitle
Nov 17, 20214Statement of changes in beneficial ownership of securities
Nov 17, 20214Statement of changes in beneficial ownership of securities
Nov 17, 20214Statement of changes in beneficial ownership of securities
Nov 17, 20214Statement of changes in beneficial ownership of securities
Nov 15, 20218-KCurrent report
Nov 5, 20214Statement of changes in beneficial ownership of securities
Nov 5, 20214Statement of changes in beneficial ownership of securities
Nov 4, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 4, 20218-KCurrent report
Nov 2, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings